Approval of Patient Group Direction
|
|
- Elfrieda Hines
- 5 years ago
- Views:
Transcription
1 Notice to all staff: NHS Hertfordshire, Patient Group Directions (PGDs) may only be used by members of the healthcare professions named on the title page and only if each professional has individually been listed by their manager as an authorised user, meeting the competency and training requirements of that PGD. Each healthcare professional using a PGD must also have signed a copy of that PGD and have one available to refer to. Staff must not download PGDs from the intranet and use them. The PGDs are only on the intranet so that clinical managers can access them when they need to authorise their team members or to check that their team is using the most recent version. Managers should also have signed the appropriate section of the PGD. Page 1 of 14
2 Patient Group Direction (PGD) Number : Supply of Azithromycin tablets or capsules for the treatment of Uncomplicated Chlamydia Trachomatis infection By Registered Nurses Working within the Hertfordshire Chlamydia Screening Programme who are employed by NHS Hertfordshire or GP Practices in either Primary Approval of Patient Group Direction This Patient Group Direction has been approved on behalf of NHS Hertfordshire Ratifying NHS Hertfordshire Board Clinical Standards Committee Sub-committee Authorising Officer for NHS Hertfordshire Signature: Dr Michael Edwards Medical Director Date: Date of Issue 1 st January 2013 Issue Number PGD Date of Review 1 st January 2015 NHS Hertfordshire is committed to being an organisation within which diversity, equality and human rights are valued. We will not discriminate either directly or indirectly and will not tolerate harassment or victimisation in relation to gender, marital status (including civil partnerships), gender reassignment, disability, race, age, sexual orientation, religion or belief, trade union membership, status as a fixed-term or part-time worker, socio-economic status and pregnancy or maternity leave status. Equality Impact Assessment (Level 1) completed Date: September 2012 This document is available electronically or in a larger font or alternative format on request. Page 2 of 14
3 Document History: To replace: Patient Group Direction (PGD) Number : Supply of Azithromycin 250mg tablets or capsules for the treatment of Uncomplicated Chlamydia Trachomatis infection by Registered Nurses Working as part of the Hertfordshire Chlamydia Screening Service who are employed by NHS or GP Practices and signatories to the PGD Progress Lead Person & Contact Number Date PGD Precedent Dipesh Songara ( ) January 2011 Updated draft Jo Jenkins ( ) September 2012 Circulation List Dr K Uthayakumar, Lead Specialist for Sexual Health HCT September 2012 Carolyn Haselden, Lead Pharmacist HCT Heather Gray, Chief Pharmacist NHS Hertfordshire Elizabeth Fisher, Health Improvement Manager, NHS Hertfordshire Dr Mike Edwards, Medical Approved & Ratified by NHS Hertfordshire CSC Review Date Date of Archiving PGD Director NHS Hertfordshire Jo Wilson Lead Nurse, Hertfordshire Chlamydia Screening Programme Table of Contents Page Front Sheet 4 Clinical Condition or Situation to which the Direction Applies 5 Description of Treatment 6 Audit 9 Characteristics and qualification required of staff 10 References 10 Management/authorisation of Patient Group Direction 12 Page 3 of 14
4 Patient Group Direction (PGD) Number : Supply of Azithromycin tablets or capsules for the treatment of Uncomplicated Chlamydia Trachomatis infection By Registered Nurses Working within the Hertfordshire Chlamydia Screening Programme who are Employed by NHS Hertfordshire or GP practices in the Primary Care Trust and signatories to the PGD Valid from: 1 st January 2013 Expiry (review) date: 1 st January 2015 After this date the direction is no longer valid. (Note: a review will be carried out sooner as a result of a critical incident, new safety or clinical information, changes in legislation or change in best practice.) Supersedes: Patient Group Direction (PGD) Number : Supply of Azithromycin 250mg tablets or capsules for the treatment of Uncomplicated Chlamydia Trachomatis infection by Registered Nurses Working as part of the Hertfordshire Chlamydia Screening Service who are employed by NHS Hertfordshire and signatories to the PGD Development of Patient Group Direction This Patient Group Direction has been developed on behalf of NHS Hertfordshire by: Name Signature Date Lead Specialist Dr S Uthayakumar 18 th HCT Pharmacist Jo Jenkins 13 th Health Improvement Service Manager Elizabeth Fisher September 2012 November Page 4 of 14
5 1. Clinical condition or situation to which the direction applies: Indication Treatment of uncomplicated genital infections due to Chlamydia trachomatis Treatment of identified contact of an index client who has had a positive Chlamydia test Criteria for inclusion Informed client consent is obtained Clients aged with laboratory evidence of Chlamydia trachomatis Identified contact of an index client who has had a positive Chlamydia test Clients at risk of re-infection as non-compliant with advice given with regards to avoidance of all sexual contact (see advice below) Clients aged 15 years and over (Clients under 16 years must be over 45kg body weight) Clients under 16 years must be assessed as competent using Frazer Guidelines Clients over the age of 24 if they are the identified sexual partner of the index client. To retreat clients who have vomited within 2 hours of taking original medication for the treatment of Chlamydia. Criteria for exclusion Client consent refused Patients with a known hypersensitivity to azithromycin or any of the macrolide or ketolide antibiotics, erythromycin or to any excipients thereof of tablet or capsule contents Patients with a known hypersensitivity to soya or peanut azithromycin tablets must be avoided. Pregnant or suspected pregnancy Breast-feeding Porphyria Hepatic impairment Renal impairment Patients at increased risk for prolonged cardiac repolarisation (predisposition to QT interval prolongation (including electrolyte disturbances, concomitant use of drugs that prolong QT interval). Client under 15 years of age Client aged under 16 years weighing less than 45 kg Client under 16 years who is felt not to be Fraser competent Clients over the age of 24 unless they are the identified sexual partner of the index patient. Male patient presenting with symptoms associated with complicated Chlamydia infection (acute testicular pain and/or swelling suspected epididymo-orchitis) Female patient presenting with symptoms associated with complicated Chlamydia infection (acute pelvic pain Page 5 of 14
6 suspected pelvic inflammatory disease) Patients with suspected re-infection Clients who are severely systemically unwell or with any serious illness Immunocompromised clients Patients with known Human Immunodeficiency Virus (HIV) infection Myasthenia Gravis Cautions/Need for further advice from a doctor Past history of cardiac arrhythmias Patients taking any of the following medication: o Ergot derivatives (including ergotamine and methysergide) o Ciclosporin o Digoxin o Nelfinavir o Coumarin-Type Oral Anticoagulants (e.g. warfarin) o Rifabutin o Reboxetine o Mizolastine o Artemether/ Lumefantrine o Ritonavir o Bromocriptine and Cabergoline o Droperidol o Colchicine o Disopyramide o Oral typhoid vaccine All other concurrent medication should be checked for interactions before supply under PGD (see appendix 1 of the British National Formulary (BNF) and the product s current Summary of Product (SPC) Characteristics) None Action if excluded Refer client to clinic doctor (if available), Genito Urinary Medicine (GUM), Sexual and Reproductive Health Service or their own GP Action if patient declines treatment Document reason(s) for exclusion and advice given Provide advice on Chlamydia Trachomatis infection and provide leaflet and make client aware of the importance of treatment Refer client to their own GP Document reason(s) for decline and advice given 2. Description of Treatment: Name, strength and formulation of drug or Azithromycin 500mg film coated tablets (as azithromycin monohydrate hemi-ethanolate) Azithromycin 250mg tablets (azithromycin (as monohydrate hemi-ethanolate) Page 6 of 14
7 or Azithromycin 250mg capsules (capsules contain azithromycin dehydrate equivalent to 250mg azithromycin) Legal status POM (prescription only medicine) Method / Route Oral Dose / Dose range 1g (2 x 500mg tablets) as a single dose or or 1 g (4 x 250mg tablets) as a single dose 1 g (4 x 250mg capsules) as a single dose (capsules should be swallowed whole at least 1 hour before or 2 hours after food (or on an empty stomach) Frequency of administration Single dose (Once during current episode by nurse prior to seeking medical advice) Quantity to be supplied Single dose (2 x 500mg tablets) or Single dose (4 x 250mg tablets) or Single dose (4 x 250mg capsules) Patient advice / Follow Also see Special considerations/ Additional information up treatment Screening, treatment, advice, follow-up and management of partner notification (contact tracing) should be in accordance with the Bedfordshire and Hertfordshire Chlamydia Screening Service, Standard Operational Procedures & Protocols Advice on Chlamydia Trachomatis infection and provide leaflets and contact cards Advice on treatment including indication, mode of action, efficacy, benefits and risks and how to take the medication Advice on possible adverse effects and drug interactions and when to seek medical advice Capsules should be swallowed whole at least 1 hour before or 2 hours after food and if relevant antacids Patient to be advised of where to obtain alternative treatment if vomiting occurs within 2 hours of taking medication Patient to be advised to abstain from sexual intercourse (no genital, oral or anal sex, even with a condom), until one week after both partners have been treated. If their partner(s) receive a one week course of treatment rather than single dose therapy then sexual intercourse should be avoided until the end of the course or if the partner(s) choose testing only until the partner(s) have a negative test Patient to be given sexual health promotion advice Warn of the risk of re-infection if has sexual contact with an untreated partner Manufacturer s written Patient Information Leaflet (PIL) should be given to the patient at the time of each supply available at Page 7 of 14
8 The patient should be advised to return as appropriate or refer client to Genito Urinary Medicine (GUM), Sexual and Reproductive Health Service or their own GP if they develop any symptoms, or they have not fully complied with treatment, or there has been a re-infection risk Advise re availability of full sexual health check and screening for other STIs at Genito Urinary Medicine (GUM) or Sexual and Reproductive Health Service clinics Advise patient on follow up care arrangements if required Emphasise importance and need for client s sexual partner(s) to be treated All patients identified with C. trachomatis should have partner notification discussed at time of treatment by a trained healthcare professional The method of partner notification agreed for each partner/contact identified should be documented, as should partner notification outcomes Attempt to contact other sexual partners within the last six months, or the most recent sexual partner if over six months All sexual partners should be offered, and encouraged to take up a full STI screen, including HIV test and if indicated hepatitis B screening +/- vaccination Initially inform Hertfordshire Chlamydia Screening Programme if the client develops any symptoms, or they have not fully complied with treatment, or there has been a re-infection risk Adverse Reactions and their Management Reporting procedure of Adverse Reactions Drug Interactions Azithromycin is generally well tolerated Very common adverse effects can include nausea, diarrhoea, wind, abdominal pain For a comprehensive list of all warnings, cautions and potential adverse reactions, refer to the current British National Formulary (BNF) and the current Summary of Product (SPC) Characteristics All adverse reactions to be recorded in the patient s notes Any adverse outcomes should be notified to the clinic doctor. If in a clinic without a doctor, client should be advised on seeing a doctor at another clinic, or their GP, and the degree of urgency A letter detailing the problem should be given to the client to take with them Complete an incident form Appropriate suspected reactions should be reported to the Commission on Human Medicines via the Yellow Card system (copies of the yellow card are available at the back of the BNF or via ( by the Nurse or the Doctor. State brand and batch number See inclusion/ exclusion criteria and special considerations/ Page 8 of 14
9 additional information Additional Facilities Following to be available at site where Patient Group Direction is operated: Azithromycin tablets or capsules, pregnancy testing kits, patient information leaflets and demonstration kits, current edition of the British National Formulary (BNF) Special Considerations / Additional Information Arrangements for handling, security, storage and labelling Records 3. Audit: For a comprehensive list of all warnings, cautions and potential adverse reactions, refer to the current British National Formulary (BNF) and the current Summary of Product (SPC) Characteristics Store in a locked drug cupboard, in a dry place, at room temperature (below 25 C), away from direct sunlight (protect from light) All medicines supplied to a patient under PGD must comply with the EC labelling and leaflet directive, i.e. must be fully labelled and an appropriate Patient Information Leaflet (PIL) supplied In all cases records should be completed immediately, be clear, accurate, legible and include: Signature and printed name of nurse, date and time Patient s name, NHS number, address, date of birth/age and consent given If under 16 years old document Fraser ruling competent Contact details of GP (if registered) Details of assessment, discussions and treatment including name (brand as appropriate), route, dose, quantity supplied, date and time, batch number and expiry date Advice given to patient (including side effects and sexual health promotion advice) Details of any adverse drug reaction and actions taken including documentation in the patient s medical record Complete Appendix 1: Chlamydia Treatment Form for each index patient and partner treated and fax to Hertfordshire Chlamydia Screening Programme or scan and to: enh-pct.hertschlamydiascreeningprogramme@nhs.net Stock Reconciliation Stock Storage Stock balances should be reconcilable with receipts, administration records and disposals on an individual patient basis. Product should be stored in accordance with the specifications of the PGD and Summary of Product Characteristics relating to the medication 4. Characteristics of Staff: Qualifications required Registered nurse with current Nursing & Midwifery Council (NMC) registration as an appropriate practitioner and employed by NHS Hertfordshire or a Hertfordshire GP Page 9 of 14
10 Practice Additional requirements Has undertaken appropriate training for working under PGDs for supply and administration of medicines Undertaken specific training relating to the Hertfordshire Chlamydia Screening Programme and the care and management of Chlamydia positive clients and their partners, and assessed as competent Training to ensure that nurses undertaking the Direction have a confident and clear understanding of the limits of the Patient Group Direction and when to refer The nurse should have had training for this Patient Group Direction, and have given written agreement to abide by it Evidenced up to date training in cardiopulmonary resuscitation skills (annually) and management of anaphylaxis (yearly) in line with the NHS Hertfordshire Mandatory Training Needs Framework Continued training Attend training dates as required and keep up to date with requirements changes The nurse is expected to ensure that he/she is up to date with the most current British National Formulary (BNF) and the most current Summary of Product Characteristics (SPC) guidance relating to the medication in the PGD The Registered Nurse must act at all times in accordance with the Nursing and Midwifery Council (NMC) code of professional conduct and Standards for medicines management, and must at all times acknowledge any limitations in their knowledge or competence. 5. References - National / Local Policies or Guidelines: 1. Current edition of the British National Formulary (BNF) Accessed September Most recent version of the Manufacturer s Summary of Product Characteristics (SPC) ( Accessed September PGD : Hertfordshire Chlamydia Screening Service: Azithromycin for the treatment of Uncomplicated Chlamydia Trachomatis infection: NHS Hertfordshire 4. National Chlamydia Screening Programme, Patient Group Direction for the administration of Azithromycin (Feb 2008) 5. The National Chlamydia Screening Programme in England, Core requirements, 5 th Edition (August 2010) 6. The British Association for Sexual Health and HIV (BASHH) Clinical Effectiveness Group Guidelines, National Guideline for the Management of Genital Tract Infection with Chlamydia trachomatis ( 7. Health Service Circular HSC 2000/026: Patient Group Directions (England only), 9 August NMC- The Code: Standards of conduct, performance and ethics for nurses and midwives (May 2008) 9. NMC- Standards for medicines management (Feb 2008) 10. Resuscitation Council (UK) Emergency Medical Treatment of Anaphylactic reactions by first medical responders and community nurses (updated January 2008) 11. Department of Health (6th April 2001) Reference Guide to Consent for Examination of Treatment. Crown copyright (ww.dh.gov.uk) Page 10 of 14
11 12. NHS Hertfordshire Consent Policy 13. National Chlamydia Screening Programme Chlamydia Connects. Issue Page 11 of 14
12 6. Management of Patient Group Direction number : Authorisation of Lead Doctor/Lead Nurse or GP (on behalf of the practice) for the supply of this medication without a prescription by the named nurse(s) below I,., Lead Doctor/Lead Nurse or General Practitioner, give authorisation for the named nurse who has signed this Patient Group Direction to supply the above named medicine as described in this direction and in accordance with current guidelines Signed Date This Patient Group Direction is to be read, agreed to and signed by all registered nurses it applies to. One copy should be given to each nurse with the original signed copy being easily accessible within the practice/clinical setting. A fully signed copy of this page to be kept by the GP Practice/Lead Nurse. By completing the section below I confirm that I have read and understood the content of this Patient Group Direction and that I fulfil the criteria set out in the Characteristics of Staff section and I am willing, competent and authorised to work under it within my professional code of conduct. Name and designation of Authorised Nurse Signature of Authorised Nurse Date Page 12 of 14
13 Appendix 1 Patient Treatment Form Hertfordshire Chlamydia Screening Programme Apsley 1 Brindley Way Apsley Hemel Hempstead HP3 9BF Tel: Fax: (safe haven) PATIENT TREATMENT FORM TO BE RETURNED TO HERTS CHLAMYDIA SCREENING PROGRAMME VIA FAX WITHIN 48 HOURS OF TREATMENT THIS INFORMATION IS VITAL TO COMPLETE PATIENT RECORDS AND FOR PAYMENT UNDER THE LES Please Test & Treat Partners Date D.O.B Name Index/Contact (delete) Contact of Lab no/name Pregnancy Risk: Symptomatic Y/N Yes/No Lab No LMP Site Code Name of Prescriber Medication Given Azithromycin 1g stat Doxycycline 100mg BD 7/7 Erythromycin 500mg 14/7 Treatment Site Treatment is free under the programme. Please use the first line treatment of Azithromycin if no contraindications. No prescription is needed. NB Do not use Azithromycin or Doxycycline during pregnancy Medication Batch Number Medication Expiry Date Date Medication Administered If unable to treat under the PGD please contact Chlamydia Screening Health Advisors on Did clients partner attend? (if applicable) Yes/No If yes please fill in a separate treatment form & return to Chlamydia Screening Health Advisors Page 13 of 14
14 Partner Name Partner D.O.B If no: Has partner been treated? Yes/No (delete as appropriate) Where were they treated With What Medication? Azithromycin/Doxycycline/Erythromycin PLEASE ADVISE NO SEXUAL CONTACT FOR 1 WEEK POST TREATMENT (2 WEEKS FOR ERYTHROMYCIN). THIS MUST ALSO TAKE INTO CONSIDERATION PARTNER TREATMENT. Signature Date Name (printed) If you have any queries please call Jackie Lamb - The Screening Support Officer on Page 14 of 14
Name Job Title Signed Date
PGD3517 PATIENT GROUP DIRECTION FOR THE SUPPLY OF AZITHROMYCIN TABS/CAPS 250mg or TABS 500mg OR SUSPENSION 600mg/15mL FOR UNCOMPLICATED GENITAL CHLAMYDIA TRACHOMATIS, UNCOMPLICATED NEISSERIA GONORRHOEA
More informationPATIENT GROUP DIRECTION FOR AZITHROMYCIN
Staff Characteristics Pharmacist registered with the RPSGB who has undertaken relevant training as specified by NHS Bristol Has undertaken appropriate training to carry out clinical assessment of patient
More informationPATIENT GROUP DIRECTION (PGD) FOR THE SUPPLY OF DOXYCYCLINE 100MG CAPSULES / TABLETS FOR THE FIRST- LINE TREATMENT OF CHLAMYDIA TRACHOMATIS INFECTION
This Patient Group Direction () must only be used by registered pharmacists who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version
More informationTHE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS
PGD3717 PATIENT GROUP DIRECTION FOR THESUPPLY OF METRONIDAZOLE 400mg TABLETSFOR THE TREATMENT OF BACTERIAL VAGINOSIS (BV) OR TRICHOMONAS VAGINALIS (TV) by registered nurses and midwives in Integrated Sexual
More informationDocument Details. Patient Group Direction
Document Details Title Patient Group Direction (PGD) CO-CODAMOL 30/500 TABLETS FOR MINOR INJURIES UNITS Trust Ref No 1956-35206 Local Ref (optional) Main points the document treatment of moderate pain
More informationName Job Title Signed Date. This Patient Group Direction is operational from: Oct 2017 Review date: Aug 19. Expires on 31 st October 2019
PGD4017 PATIENT GROUP DIRECTION FOR THE SUPPLY OF ACICLOVIR TABLETS FOR THE TREATMENT OF GENITAL HERPES SIMPLEX INFECTIONS by registered nurses and midwives in Integrated Sexual Health services employed
More informationPatient Group Drection (PGD) Number : Administration of Human Papillomavirus Vaccine (HPV) Types 6, 11, 16 and 18 (Gardasil )
Notice to all staff: The Patient Group Directions (PGDs) for the Hertfordshire and South Midlands Area Team may only be used by members of the healthcare professions named on the title page, and only if
More informationDocument Details. notification of entry onto webpage
Document Details Title Patient Group Direction (PGD) Administration of sodium chloride 0.9% injection by registered professionals Trust Ref No 1987-38096 Local Ref (optional) Main points the document As
More informationNHS Fife. Patient Group Direction for Named Community Pharmacists to Supply
Patient Group Direction for Named Community Pharmacists to Supply Senna tablets 7.5mg or Senna syrup 7.5mg/5ml (Total sennosides calculated as sennoside B) For patients aged 16 years and older prescribed
More informationPatient Group Direction (PGD) template
Patient Group Direction (PGD) template Initial supply of doxycycline 100mg capsules to adults and children aged eight (8) years and over exposed to a suspected biological agent Version no: 2014/2 Valid
More informationPatient Group Direction for ACICLOVIR (Version 02) Valid From 1 October September 2019
Version Control This PGD has been agreed by the following organisations FCMS PDS Medical Doncaster CCG Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire CCGs Change history
More informationPatient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders.
Patient Group Direction for the supply of Fusidic Acid Cream 2% to patients aged over 2 years old receiving treatment from NHS Borders. This document authorises the supply of Fusidic Acid Cream 2% by registered
More informationJob Title Name Signature Date
Supply of Fluconazole 150mg capsule by Community Pharmacists working in Forth Valley Pharmacies under NHS Minor Ailment Service. Protocol Number 125 Version 5 Date protocol prepared: November 2014 Date
More informationGG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2018/1562 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation in adults
More informationGG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2017/1426 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Immunisation
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2015
Patient Group Direction For The Supply Of Trimethoprim For The Treatment Of Women With Uncomplicated Urinary Tract Infections By Nurses And Pharmacists Working Within NHS Grampian Community Pharmacies
More informationxrfslt \j,3 0+ {6^1 Otc(L!?i:lr+ NHS FIFE PRIMARY CARE THIS PATIENT GROUP DIRECTION HAS BEEN APPROVED BY:
NHS FIFE PRIMARY CARE Patient Group Direction for Named Nurses in Contraception and Sexual Health Clinics to Supply Clotrim azole lo/o cream TO WOMEN CLIENTS for use in the treatment of vaginal candidiasis
More informationPATIENT GROUP DIRECTION (PGD) FOR:
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication For treatment of genital Chlamydia and / or epidemiological
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria: Cautions/Need for
More informationNHS Greater Glasgow & Clyde Patient Group Direction (PGD) for Healthcare Professionals Typhoid vaccine (intra muscular administration)
GG&C PGD ref no: 2017/1523 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: For active immunisation in adults
More informationPATIENT GROUP DIRECTION (PGD) FOR:
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication For the treatment of genital Chlamydia and/or epidemiological
More informationCLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD)
CLINICAL PROTOCOL FOR THE DEVELOPMENT AND IMPLEMENTATION OF PATIENT GROUP DIRECTIONS (PGD) DEFINITION A Patient Group Direction (PGD) is a specific written instruction for the supply and administration
More informationPATIENT GROUP DIRECTION (PGD) FOR Metronidazole 400mg Tablets
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationGG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT
GG&C PGD ref no: 2011/841 YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Exclusion criteria:
More informationPlease call the Pharmacy Medicines Unit on or for a copy.
Title: PATIENT GROUP DIRECTION FOR THE SUPPLY OF FLUCONAZOLE 150MG UNDER THE MINOR AILMENT SERVICE Identifier: Across NHS Boards Organisation Wide Directorate Clinical Service Sub Department Area This
More informationPATIENT GROUP DIRECTION (PGD) FOR
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationIBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
IBUPROFEN PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its
More informationExpiry Date: January 2009 Template Version: Page 1 of 7
YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Clinical Condition Indication: Inclusion criteria: Patients who require an antihistamine
More informationPatient Group Direction for Aspirin 300mg Version: 02 Start Date: 1 st October 2017 Expiry Date: 30 th September 2019
THIS PATIENT GROUP DIRECTION HAS BEEN AGREED BY THE FOLLOWING ORGANISATIONS: CLINICAL COMMISSIONING GROUP: Doncaster CCG, Lancashire CCGs including East Lancashire, Fylde and Wyre and North Lancashire
More informationAppendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD)
Appendix 3 Cardiac Catheter Lab at Musgrove Park Hospital PATIENT GROUP DIRECTION (PGD) PGD for the supply/administration of: Lidocaine 1% and Adrenaline 1:200,000 Master document reference number: This
More informationPatient Group Direction For the supply of Fusidic Acid 2% Cream
Patient Group Direction For the supply of Fusidic Acid 2% Cream This Patient Group Direction (PGD) is a specific written instruction for the supply of Fusidic Acid 2% Cream to groups of patients who may
More informationNational Emergency Medicine Programme. Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Department
National Emergency Medicine Programme Protocol for the administration of Paracetamol (Acetaminophen) at Triage in the Emergency Date: November 2016 Table of Contents 1.0 Critical Elements... 3 2.0 Clinical
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% FOR THE TREATMENT OF IMPETIGO BY COMMUNITY PHARMACISTS UNDER THE PHARMACY FIRST SERVICE IN NHS HIGHLAND THE COMMUNITY PHARMACIST SEEKING
More informationPATIENT GROUP DIRECTION (PGD) FOR Amoxicillin 250mg/5ml Suspension
Antibiotic Oral (tablet/capsule/suspension) PATIENT GROUP DIRECTION (PGD) FOR YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT Caution: This
More informationPROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS
STANDARD OPERATING PROCEDURE PROCESS FOR INITIATING A SYRINGE DRIVER FOR COMMUNITY NURSE PATIENTS OUT OF HOURS Issue History Issue Version one Purpose of Issue/Description of Change To facilitate patients
More informationCLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
CLINICAL GUIDELINE FOR IPRATROPIUM BROMIDE NEBULISER INHALER PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical
More informationSupply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 2 Date protocol prepared: October 2017 Date protocol due for review: October 2019 Expiry date: October
More informationPARACETAMOL PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline
PARACETAMOL PATIENT GROUP DIRECTION CHILD HEALTH 1. Aim/Purpose of this Guideline 1.1. This Patient Group Direction (PGD) applies to all nursing and clinical staff in the Child Health Department and its
More informationPATIENT GROUP DIRECTION. Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix )
PATIENT GROUP DIRECTION Administration of: By: Practice Nurses Hepatitis A + B Vaccine (Twinrix, Twinrix paediatric, Ambirix ) In: General Practice It is the responsibility of the professional working
More informationPATIENT GROUP DIRECTION (PGD)
Reference: XXXXXXX PATIENT GROUP DIRECTION (PGD) Initial supply of doxycycline 100mg capsules to adults and children aged 8 years and over exposed to a known or suspected release of anthrax For the initial
More informationConsultation Group: See relevant page in the PGD. Review Date: October 2016
Patient Group Direction For The Administration Of Adrenaline (Epinephrine) By Trained Nurses In The Management Of Cardiac Arrest In The Medical High Dependency Unit/Coronary Care Unit (MHDU/CCU) Working
More informationNHS Lothian Patient Group Direction Version: 001
PATIENT GROUP DIRECTION FOR THE SUPPLY OF FUSIDIC ACID CREAM 2% TO TREAT MINOR STAPHYLOCOCCAL SKIN INFECTIONS (IMPETIGO) IN PATIENTS AGED OVER 2 YEARS BY PHARMACISTS WORKING WITHIN NHS LOTHIAN COMMUNITY
More informationPatient Group Direction Policy
Approval Process Patient Group Direction Policy Lead Author Developed by Sarah Woodley, Community Health Services Pharmacist 01223 474903 sarah.woodley@cambridgeshirepct.nhs.uk Sarah Woodley, Gillian Ascough,
More informationPGDs are permitted for use only by registered health professionals (see enclosed link for full list
NHS England North - Yorkshire and the Humber Region Protocol for the Development, Authorisation and Use of Patient Group Directions for the National Immunisation Programmes 1. Introduction The preferred
More informationHepatitis B Immunisation procedure SOP
Hepatitis B Immunisation Procedure SOP Standard Operating Procedure (SOP) Ref No: 1992 Version: 3 Prepared by: Karen Bennett Presented to: Care and Clinical Policies Sub Group Ratified by: Care and Clinical
More informationSTANDARD OPERATING PROCEDURE FOR SAFE AND SECURE MANAGEMENT OF CONTROLLED DRUGS WITHIN PRIMARY CARE DIVISION.
STANDARD OPERATING PROCEDURE FOR SAFE AND SECURE MANAGEMENT OF CONTROLLED DRUGS WITHIN PRIMARY CARE DIVISION. Issue History Oct 12 Issue Version Two Purpose of Issue/Description of Change To ensure implementation
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Unlicensed Medicines Policy
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Unlicensed Medicines Policy Version.: 2.4 Effective From: 13 October 2016 Expiry Date: 13 October 2018 Date Ratified: 12 October 2016 Ratified By:
More informationSupply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 version 1
Supply of Fusidic acid 2% cream for impetigo by Community Pharmacists Protocol Number 472 Date protocol prepared: December 2015 Date protocol due for review: December 2017 This patient group direction
More informationPROTOCOL FOR THE ADMINISTRATION OF SENNA. Formulary and Prescribing Guidelines
PROTOCOL FOR THE ADMINISTRATION OF SENNA Formulary and Prescribing Guidelines Introduction This protocol allows for the administration of Senna by a registered nurse without a prescription from a doctor
More informationSupply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over.
Supply of Fusidic Acid Cream 2% by Community Pharmacists for the treatment of impetigo in patients 2 years of age and over. November 2017 Review Nov 2019 Signatures of those developing the Patient Group
More informationPatient Group Direction For The Administration Of Sodium Chloride (0.9%) Via Nebulisation By Physiotherapists Working Within NHS Grampian
NHS Grampian Patient Group Direction For The Administration Of Sodium Chloride (0.9%) Via Nebulisation By Physiotherapists Working Within NHS Grampian Lead Author: Consultation Group: Approver: Highly
More informationThis guideline is for nursing staff within the Pain Services assisting with the administration of botulinum toxin.
CLINICAL GUIDELINE FOR THE SAFE ADMINISTRATION OF BOTULINUM NEURO TOIN FOR INJECTION within the PAIN SERVICE. Botox and eomin (trade names) 1. Aim/Purpose of this Guideline This guideline is for nursing
More informationAll areas of the Trust All Trust staff All Patients Deputy Chief Nurse & Chief Pharmacist Final
Trust Policy and Procedure Document Ref. No: PP(15)233 Non-Medical Prescribing Policy For use in: For use by: For use for: Document owner: Status: All areas of the Trust All Trust staff All Patients Deputy
More informationSocial care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1
Managing medicines in care homes Social care guideline Published: 14 March 2014 nice.org.uk/guidance/sc1 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION
SUPPLY BY PHARMACISTS OF A NON-PRESCRIPTION MEDICINAL PRODUCT CONTAINING LEVONORGESTREL (NORLEVO 1.5MG TABLETS) AS EMERGENCY HORMONAL CONTRACEPTION GUIDANCE FOR PHARMACISTS ON SAFE SUPPLY TO PATIENTS (This
More informationMedicine Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP Version 1, June 2017
Medicine Protocol for the Administration of Inactivated Influenza Vaccine (Split Virion) BP to nurses, midwives, healthcare workers, agency staff, contract workers and volunteers by registered nurses and
More informationNon Medical Prescribing Policy
Non Medical Prescribing Policy Author: Sponsor/Executive: Responsible committee: Ratified by: Consultation & Approval: (Committee/Groups which signed off the policy, including date) This document replaces:
More informationFOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING
STANDARD OPERATING PROCEDURE FOR MEDICINE ADMINISTRATION IN COMMUNITY NURSING Issue History Issue Version One Purpose of Issue/Description of Change To promote safe and effective medicine administration
More informationPOLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case
POLICY FOR ANTICIPATORY PRESCRIBING FOR PATIENTS WITH A TERMINAL ILLNESS Just in Case DOCUMENT NO: DN116 Lead author/initiator(s): Sarah Woodley Community Health Services Pharmacist sarah.woodley@ccs.nhs.uk
More informationUncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE. SECTION 9(a) UNLICENSED MEDICINES
Uncontrolled when printed NHS AYRSHIRE & ARRAN CODE OF PRACTICE FOR MEDICINES GOVERNANCE SECTION 9(a) UNLICENSED MEDICINES BACKGROUND and PURPOSE Under the Medicines Act 1968 (EEC Directive 65/65), a company
More informationManaging medicines in care homes
Managing medicines in care homes http://www.nice.org.uk/guidance/sc/sc1.jsp Published: 14 March 2014 Contents What is this guideline about and who is it for?... 5 Purpose of this guideline... 5 Audience
More informationChlamydia Screening. Specification for a Pharmacy Local Enhanced Service Date: 1 st June st March 2012
Chlamydia Screening Specification for a Pharmacy Local Enhanced Service Date: 1 st June 2011 31 st March 2012 Introduction All pharmacies are expected to provide essential and those advanced services they
More informationPROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS
PROCEDURE FOR THE ADMINISTRATION OF HOMELY REMEDIES IN COMMUNITY HOSPITALS Document Details Title Procedure for the administration of Homely Remedies in Community Hospitals Trust Ref No 1896-36344 Local
More informationSwitch protocol: Brands to generic equivalent
Switch protocol: Brands to generic equivalent Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians. These protocols are produced by the NY&AWC MM team hosted by HaRD CCG for
More informationSTANDARD OPERATING PROCEDURE ADMINISTRATION OF HEPARIN FLUSHES VIA CENTRAL INTRAVENOUS ACCESS DEVICES
STANDARD OPERATING PROCEDURE ADMINISTRATION OF HEPARIN FLUSHES VIA CENTRAL INTRAVENOUS ACCESS DEVICES First Issued Issue Version One Purpose of Issue/ Description of Change To promote the safe administration
More informationImproving sexual health is a key national public health priority (Healthy Lives, Healthy People, Department of Health, 2010).
SERVICE SPECIFICATION Service Specification No. Service name Pharmacy Enhanced Services - chlamydia treatment Plymouth City Council Lead Laura Juett, Public Health Policy and Service Development Manager
More informationAppendix 2. Community Pharmacy Emergency Hormonal Contraception Service
Appendix 2 Community Pharmacy Emergency Hormonal Contraception Service 2014 until end November 2016 Contents Executive Summary... 3 Aims and intended service outcomes of the service... 3 Brief service
More informationNON-MEDICAL PRESCRIBING POLICY
NON-MEDICAL PRESCRIBING POLICY To be read in conjunction with the Medicines Policy, Controlled Drug Policy and the FP10 Prescribing Forms Policy Version: 5 Date of issue: August 2017 Review date: August
More informationConsultation Group: See relevant page in the PGD. Review Date: May Expiry Date: May 2020
NHS...... Grampian Patient Group Direction For The Administration Of Lidocaine Hydrochloride 1% Injection As Infiltration Anaesthesia For Insertion/Removal Of Tunnelled Central Venous Catheters By Nurses/Radiographers
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Introduction and Development of New Clinical Interventional Procedures
The Newcastle upon Tyne Hospitals NHS Foundation Trust Introduction and Development of New Clinical Interventional Procedures Version No.: 2.1 Effective From: 27 November 2017 Expiry Date: 7 January 2019
More informationDerby Hospitals NHS Foundation Trust. Drug Assessment
Drug Assessment for Preparation and Administration of Oral, Enteral, Ophthalmic, Topical, PR, PV, Inhaled, Subcutaneous and Intramuscular Medicines to Patients (N.B. The preparation and administration
More informationNOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST MEDICINES CODE OF PRACTICE MEDICINES MANAGEMENT WHEN PATIENTS ARE DISCHARGED FROM HOSPITAL
NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST MEDICINES CODE OF PRACTICE MEDICINES MANAGEMENT WHEN PATIENTS ARE DISCHARGED FROM HOSPITAL Reference CL/MM/024 Date approved 13 Approving Body Directors Group
More informationGUIDELINES FOR MANAGEMENT OF CHLAMYDIA POSITIVE CLIENTS AND THEIR PARTNERS
DRAFT 01/11/06 GUIDELINES FOR MANAGEMENT OF CHLAMYDIA POSITIVE CLIENTS AND THEIR PARTNERS CHLAMYDIA SCREENING OFFICE ADDRESS: Cornerstones Health Centre 2 Graham St Beswick M11 3AA Tel: 0845 330 6363 Fax
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION. Version 5 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE INDIGESTION Version 5 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse MAUP
More informationNHS North Somerset Clinical Commissioning Group
NHS North Somerset Clinical Commissioning Group Medicines Policy - Safe and Secure Handling of Medicines Approved by: Quality and Assurance Group Ratification date: July 2013 Review date: June 2016 Page
More informationNon Medical Prescribing Policy Register No: Status: Public
Non Medical Prescribing Policy Policy Register No: 07049 Status: Public Developed in response to: Department of Health Policies, Prescribing Guidance & Legislation Contributes to CQC Outcome: 9 Consulted
More informationNon-Medical Prescribing Passport. Reflective Log And Information
Non-Medical Prescribing Passport Reflective Log And Information Non-Medical Prescribing Continued Profession Development Log NMPs must refer to their regulatory bodies requirements for maintaining and
More informationPGD5417. Clinical Performance Director of Nursing Allison Bussey
PGD5417 Patient Group Direction Administration of Adrenaline (Epinephrine) 1:1000 (1mg/ml) Injection By Registered Nurses and Midwives employed by South Staffordshire & Shropshire Healthcare Foundation
More informationSERVICE SPECIFICATION FOR THE PROVISION OF LONG-ACTING REVERSIBLE CONTRACEPTION SUB-DERMAL CONTRACEPTIVE IMPLANTS IN BOURNEMOUTH, DORSET AND POOLE
Revised for: 1 April 2015 Updated: 16 April 2015 Appendix 2.2 SERVICE SPECIFICATION FOR THE PROVISION OF LONG-ACTING REVERSIBLE CONTRACEPTION SUB-DERMAL CONTRACEPTIVE IMPLANTS IN BOURNEMOUTH, DORSET AND
More informationSection Title. Prescribing competency framework Catherine Picton, Lead author
Prescribing competency framework Catherine Picton, Lead author What is in this presentation Context Uses of the competency framework Scope of the updated prescribing competency framework Introduction to
More informationMedical Needs Policy. Policy Date: March 2017
Medical Needs Policy Policy Date: March 2017 Renewal Date: March 2017 Equality Statement This policy takes into account the provisions of the Equality Act 2010 and advances equal opportunities for all.
More informationAnaphylactic Reaction Emergency Treatment Reference Number:
This is an official Northern Trust policy and should not be edited in any way Anaphylactic Reaction Emergency Treatment Reference Number: NHSCT/12/551 Target audience: Nursing Staff Groups included are:
More informationPROCEDURE FOR IMMUNISATION
Issue History Issue Version Purpose of Issue/Description of Change Planned Review Date One To promote the safe administration of vaccines 2014 Named Responsible Officer:- Approved by Date Medicines Governance
More informationADMINISTRATION OF MEDICATION POLICY G&F ALTERNATIVE PROVISION SCHOOL
Gloucester & Forest Alternative Provision School ADMINISTRATION OF MEDICATION POLICY G&F ALTERNATIVE PROVISION SCHOOL Date:September 2013 PURPOSE The guidance in this policy is to ensure that pupils with
More informationHertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust
Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust STANDARD OPERATING PROCEDURE FOR RESEARCH Definition of Responsibilities for Externally
More informationIt is essential that patients are aware of, and in agreement with, their referral to palliative care.
Title: Directorate: Responsible for review: Ratified by: CHRONIC HEART FAILURE REFERRAL TO PALLIATIVE CARE SERVCES Palliative Care Consultant in Palliative Care Care and Clinical Policies Group Ref No:
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Medicines Reconciliation Policy and Procedure for Adult and Paediatric Patients
The Newcastle upon Tyne Hospitals NHS Foundation Trust Medicines Reconciliation Policy and Procedure for Adult and Paediatric Patients Version.: 2.0 Effective From: 15 March 2018 Expiry Date: 15 March
More informationGROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS. Version 4 December 2017
GROUP PROTOCOL FOR THE MANAGEMENT OF SIMPLE MOUTH ULCERS Version 4 December 2017 RATIFYING COMMITTEE Drugs and Therapeutics Group DATE RATIFIED MAUP EXPIRES December 2020 EXECUTIVE SPONSOR Chief Nurse
More informationMedication Policy. Revised March 2013
Medication Policy Revised March 2013 Contents page Content Page No. Covert Medication Background 3-4 Domestic Medicines 5 Medication 6-7 Non-Compliance with Medication 8 Use of Oxygen Policy Statement
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust
The Newcastle upon Tyne Hospitals NHS Foundation Trust Procedure for registration and supply of prophylaxis to the immediate household contacts of patients admitted with meningococcal disease Version.:
More informationMandatory Competency Assessment for Medicines Management (Not Injectable Medicines) for Registered Practitioners IN HOSPITAL
Mandatory Competency Assessment for Medicines Management (Not Injectable Medicines) for Registered Practitioners IN HOSPITAL Document Author Written by: Lead Pharmacist/Lead Technician Medicines Use and
More informationPOLICY FOR X RAY REFERRAL BY QUALIFIED NURSE PRACTITIONERS WORKING IN GENERAL PRACTICE
POLICY FOR X RAY REFERRAL BY QUALIFIED NURSE PRACTITIONERS WORKING IN GENERAL PRACTICE APPROVED BY: Chief Nurse May 2016 EFFECTIVE FROM: May 2016 REVIEW DATE: May 2018 Version Control Policy Category:
More informationDocument Title: Investigator Site File. Document Number: 019
Document Title: Investigator Site File Document Number: 019 Version: 1.1 Ratified by: R&D Committee Date ratified: 03/10/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationThe Newcastle upon Tyne Hospitals NHS Foundation Trust. Strong Potassium Solutions Safe Handling and Storage
The Newcastle upon Tyne Hospitals NHS Foundation Trust Strong Potassium Solutions Safe Handling and Storage Version : 5.3 Effective From: 19 January 2016 Expiry Date: 19 January 2019 Date Ratified: 14
More informationPHARMACEUTICAL REPRESENTATIVE POLICY NOVEMBER This policy supersedes all previous policies for Medical Representatives
PHARMACEUTICAL REPRESENTATIVE POLICY VEMBER 2017 This policy supersedes all previous policies for Medical Representatives Policy title Pharmaceutical Representative Policy Policy PHA39 reference Policy
More informationCLINICAL AUDIT. The laboratory investigation of. UTI in females. in primary care
CLINICAL AUDIT The laboratory investigation of UTI in females in primary care Valid to December 2018 bpac nz better medicin e Background Approximately 50% of all females will have a urinary tract infection
More informationThe Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services
Standard Operating Procedure 2 (SOP 2) The Prescribing, Monitoring and Administration of Depot / Long Acting IM Medication within Community Mental Health Services Why we have a procedure? Black Country
More informationPHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK
PHARMACIST INDEPENDENT PRESCRIBING MEDICAL PRACTITIONER S HANDBOOK 0 CONTENTS Course Description Period of Learning in Practice Summary of Competencies Guide to Assessing Competencies Page 2 3 10 14 Course
More informationAdult Protocol Intermittent Catheterisation
Adult Protocol Intermittent Catheterisation Page 1 of 8 Policy reference: Continence Introduction Adult Protocol Intermittent Catheterisation This protocol covers management of incomplete bladder emptying
More informationThe Newcastle Upon Tyne Hospitals NHS Foundation Trust. Use of Patients Own Drugs (PODs)
The Newcastle Upon Tyne Hospitals NHS Foundation Trust Use of Patients Own Drugs (PODs) Version.: 2.2 Effective From: 20 January 2016 Expiry Date: 20 January 2019 Date Ratified: 13 January 2016 Ratified
More information